Business Monitor International


Austria Pharmaceuticals & Healthcare Report

Published 06 February 2014

  • 67 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Austria Pharmaceuticals & Healthcare Report

BMI View : We believe Austria's pharmaceutical spending will post weak growth over the medium term, due to the state's need to contain fiscal deficits. Although an improving economic climate in Austria's primary trading partner, Germany, has improved outlook for the industry, growth will remain subdued in the medium term and strengthening EUR-USD will affect returns for overseas investors. T he Austrian pharmaceutical market is relatively small in absolute terms in comparison with its EU15 neighbours, yet has one of the highest global per capita expenditures on healthcare. This is due to its relatively small population, high burden of non-communicable diseases and ageing population.

Headline Expenditure Projections

  • Pharmaceuticals: EUR4.58bn (US$6.09bn) in 2013 to EUR4.73bn (US$6.0bn) in 2014; +3.2% in local currency terms and -1.5% in US dollar terms.

  • Healthcare: EUR33.47bn (US$44.52bn) in 2013 to EUR34.37bn (US$43.65bn) in 2014; +2.7% in local currency terms and -2.0% in US dollar terms.

Risk/Reward Rating

Based on the inherent Rewards and Risks for drugmakers operating in the country, Austria has been assigned an RRR score of 71.5, coming third out of the 15 pharmaceutical markets in Western Europe. Slow economic recovery in Austria, following what has been a difficult year for Europe, makes it one of the more attractive markets for pharmaceutical companies.

Key Trends & Developments

  • Although prevalent throughout other Western European countries, generic prescribing has been applied as systematically in Austria. Branded pharmaceuticals by far dominate prescription drug sales.

  • Austria's ageing population and its chronic disease burden will provide growth opportunities for pharmaceutical companies in the long term.

  • Drug price restrictions within the supply chain will continue to remain in effect for the long term.

  • The reimbursement model will continue to include cost-effectiveness as a key determinant of reimbursing and pricing for new drugs.

Table of Contents

BMI Industry View
7
SWOT
9
Political
10
Economic
11
Business Environment
12
Industry Forecast
13
Pharmaceutical Market Forecast
13
Table: Austria Pharmaceutical Sales, Historical Data and Forecasts
14
Healthcare Market Forecast
14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts, 2010-2013
16
Table: Government Healthcare Expenditure, Historical Data And Forecasts, 2010-2018
16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts, 2010-2018
17
Prescription Drug Market Forecast
18
Table: Austria Prescription Drug Market Indicators, Historical Data and Forecasts
19
Patented Drug Market Forecast
20
Table: Austria Patented Drug Market Indicators, Historical Data and Forecasts, 2010-2018
21
Generic Drug Market Forecast
21
Table: Austria Generic Drug Market Indicators, Historical Data and Forecasts
22
OTC Medicine Forecast
23
Table: Austria OTC Medicine Market Indicators, Historical Data and Forecasts
24
Macroeconomic Forecasts
25
Economic Analysis
25
Table: Austria - Economic Activity
32
Industry Risk Reward Ratings
33
Western Europe Risk/Reward Ratings
33
Austria Risk/Reward Ratings
37
Rewards
38
Risks
38
Market Overview
40
Industry Trends And Developments
42
Epidemiology
42
Regulatory Development
44
Competitive Landscape
49
Pharmaceutical Distribution
51
Pharmaceutical Wholesale
51
Table: Members Of ARGE Pharmazeutika, 2011
52
Pharmaceutical Retail
53
Table: Pharmacy Outlets by Type, 2005-2009
54
Table: Pharmacy Outlets by State, 2005-2009
54
Demographic Forecast
56
Table: Austria's Population By Age Group, 1990-2020 ('000)
57
Table: Austria's population By Age Group, 1990-2020 (% of total)
58
Table: Austria's Key Population Ratios, 1990-2020
59
Table: Austria's Rural And Urban Population, 1990-2020
59
Glossary
60
Methodology
62
Pharmaceutical Expenditure Forecast Model
62
Healthcare Expenditure Forecast Model
62
Notes On Methodology
63
Risk/Reward Ratings Methodology
64
Ratings Overview
65
Table: Pharmaceutical Risk/Reward Ratings Indicators
65
Indicator Weightings
66

The Austria Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Austria Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Austrian pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Austria to test other views - a key input for successful budgeting and strategic business planning in the Austrian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Austrian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Austria.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc